« Return to News | Clinical Intelligence

OncoGenex reports promising preclinical cancer data

Monday, March 5, 2012 06:09 AM

OncoGenex Pharmaceuticals’ compound OGX-427 shows potential for augmenting anti-cancer therapies and delay tumor progression.

OGX-427 is designed to inhibit Heat Shock Protein 27 (Hsp27), which is expressed in many types of cancers including prostate, bladder, breast and non-small cell lung cancer. Overexpression of Hsp27 is associated with treatment resistance and negative clinical outcomes in patients with various tumor types.

The preclinical study of OGX-427 tested whether the Hsp27 inhibitor worked synergistically with Heat Shock Protein 90 (Hsp90) inhibitors to disrupt protein homeostasis and maximally stress cancer cells to improve treatment outcomes. The study showed when Hsp27 was decreased via OGX-427 treatment, the effect of the Hsp90 inhibitors was enhanced and tumor cell death was observed. The authors concluded OGX-427 in combination with Hsp90 inhibitors potentiated the effects of Hsp90, delayed tumor growth and prolonged survival in murine prostate cancer models.

"As cancers become resistant to standard therapies we need to identify new ways to continue to stress and effectively treat them," said Dr. Martin Gleave, director of The Vancouver Prostate Centre at the University of British Columbia and researcher on this study. "This study confirms the potential utility of inhibiting cell-survival proteins like Hsp27 and the potential for OGX-427 to be included in anti-cancer treatment combination strategies."

OGX-427 is currently being evaluated in several ongoing phase I and II studies in prostate and bladder cancers.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.